{"id":22907,"date":"2023-01-12T00:20:00","date_gmt":"2023-01-11T16:20:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22907"},"modified":"2025-01-25T00:25:22","modified_gmt":"2025-01-24T16:25:22","slug":"beigene-outlines-global-rd-strategy-at-j-p-morgan-healthcare-summit","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22907","title":{"rendered":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit"},"content":{"rendered":"\n<p>China-based biotech BeiGene (Nasdaq: BGNE, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>) provided an update on its company strategy and R&amp;D plans at this week\u2019s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm\u2019s globally disruptive R&amp;D model, which includes in-house discovery capabilities and new treatment modalities set to drive future growth.<\/p>\n\n\n\n<p><strong>Key Takeaways from the Presentation<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Discovery Pipeline: BeiGene expects its discovery pipeline to generate 10 Investigational New Drug (IND) applications each year going forward.<br>Revenue Milestone: Revenues for 2022 are set to break through the USD 1 billion mark for the first time.<\/li>\n\n\n\n<li>Brukinsa Growth: Brukinsa growth is expected to be boosted by approval decisions this year in sizeable chronic lymphocytic leukemia (CLL) indications in the US, China, Canada, and Australia.<\/li>\n\n\n\n<li>Tislelizumab Approvals: Tislelizumab is expected to gain approvals in the US potentially later this year once onsite inspections are completed in China, for second-line esophageal squamous cell carcinoma (ESCC) in partnership with Novartis. This will be followed by submissions for first-line ESCC and gastric cancer.<\/li>\n<\/ul>\n\n\n\n<p><strong>BeiGene Reaching World-Class Scale<\/strong><br>Oyler emphasized BeiGene\u2019s increasingly globally competitive scale, with 2022 revenues set to exceed USD 1 billion for the first time. As previously reported, Q1-Q3 revenues already reached USD 962 million after a 109% year-on-year expansion. Sales are being generated by 16 commercial-stage products marketed by a global team of over 3,500, including the two cornerstone in-house discoveries: the programmed death-1 (PD-1) inhibitor tislelizumab and the Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib).<\/p>\n\n\n\n<p>The company employs over 9,000 people, including 950 discovery scientists, making it one of the largest oncology-focused teams globally. With 2,700 clinical development and medical affairs staff, BeiGene operates \u201clargely CRO-free,\u201d generating significant cost and time savings. This allows the firm to conduct development at a 30% discount to the industry standard.<\/p>\n\n\n\n<p><strong>Strength of the Pipeline<\/strong><br>Oyler highlighted the strength of BeiGene\u2019s pipeline, which includes over 60 preclinical programs, with the majority viewed as potential best- or first-in-class candidates. The expectation is for 10 IND filings each year for new molecules emerging from the pipeline.<\/p>\n\n\n\n<p><strong>Key Pipeline Candidates<\/strong><br>Oyler identified three key pipeline candidates with significant potential:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BGB-11417: A BCL-2-targeted therapy, positioned as a best-in-class competitor to first-generation drug venetoclax (AbbVie\u2019s Venclexta) for the treatment of relapsed or refractory CLL and mantle cell lymphoma (MCL).<\/li>\n\n\n\n<li>BGB-15025: A first-in-class inhibitor of the novel immune checkpoint HPK1, complementing BeiGene\u2019s other immunotherapy pipeline candidates targeting TIGIT, OX40, TIM-3, and LAG3.<\/li>\n\n\n\n<li>BGB-16673: A chimeric degradation activating compound (CDAC), BeiGene\u2019s term for proteolysis targeting chimera (PROTAC) technology or targeted protein degradation. As noted by Oyler, \u201cProtein degradation is a field in which BeiGene will be a major player.\u201d<\/li>\n<\/ul>\n\n\n\n<p><strong>Future Outlook<\/strong><br>BeiGene&#8217;s presentation at the J.P. Morgan Healthcare Summit underscores its commitment to innovation and global competitiveness. With a robust pipeline, significant revenue growth, and a focus on disruptive R&amp;D, BeiGene is poised to make a meaningful impact in the global oncology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[185,2092,30,16,20,847,107,18,25,70],"class_list":["post-22907","post","type-post","status-publish","format-standard","hentry","category-company","tag-beigene","tag-beone-medicines","tag-biotech","tag-cancer","tag-finance","tag-hkg-6160","tag-immunotherapy","tag-pd-1-l1","tag-potential-first-in-class","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&amp;D plans at this week\u2019s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm\u2019s globally disruptive R&amp;D model, which includes in-house discovery capabilities and new treatment modalities set to drive future growth.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22907\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22907\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-11T16:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T16:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit\",\"datePublished\":\"2023-01-11T16:20:00+00:00\",\"dateModified\":\"2025-01-24T16:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907\"},\"wordCount\":501,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"Biotech\",\"Cancer\",\"Finance\",\"HKG: 6160\",\"Immunotherapy\",\"PD-1\\\/L1\",\"Potential first-in-class\",\"TPD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22907#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22907\",\"name\":\"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-11T16:20:00+00:00\",\"dateModified\":\"2025-01-24T16:25:22+00:00\",\"description\":\"China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&D plans at this week\u2019s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm\u2019s globally disruptive R&D model, which includes in-house discovery capabilities and new treatment modalities set to drive future growth.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22907\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22907#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit - Insight, China&#039;s Pharmaceutical Industry","description":"China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&D plans at this week\u2019s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm\u2019s globally disruptive R&D model, which includes in-house discovery capabilities and new treatment modalities set to drive future growth.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22907","og_locale":"en_US","og_type":"article","og_title":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22907","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-11T16:20:00+00:00","article_modified_time":"2025-01-24T16:25:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22907#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22907"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit","datePublished":"2023-01-11T16:20:00+00:00","dateModified":"2025-01-24T16:25:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22907"},"wordCount":501,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeiGene","BeOne Medicines","Biotech","Cancer","Finance","HKG: 6160","Immunotherapy","PD-1\/L1","Potential first-in-class","TPD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22907#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22907","url":"https:\/\/flcube.com\/?p=22907","name":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-11T16:20:00+00:00","dateModified":"2025-01-24T16:25:22+00:00","description":"China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&D plans at this week\u2019s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm\u2019s globally disruptive R&D model, which includes in-house discovery capabilities and new treatment modalities set to drive future growth.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22907#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22907"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22907#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Outlines Global R&amp;D Strategy at J.P. Morgan Healthcare Summit"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22907"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22907\/revisions"}],"predecessor-version":[{"id":22908,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22907\/revisions\/22908"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}